Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Profit After Tax (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Profit After Tax data on record, last reported at -$26.7 million in Q3 2025.

  • For Q3 2025, Profit After Tax rose 33.54% year-over-year to -$26.7 million; the TTM value through Sep 2025 reached -$149.3 million, up 16.78%, while the annual FY2024 figure was -$165.8 million, 43.27% up from the prior year.
  • Profit After Tax reached -$26.7 million in Q3 2025 per ZNTL's latest filing, up from -$26.9 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $10.1 million in Q1 2024 and bottomed at -$112.5 million in Q2 2023.
  • Average Profit After Tax over 4 years is -$53.2 million, with a median of -$55.3 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: surged 115.91% in 2024, then plummeted 579.53% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$55.3 million in 2022, then decreased by 10.41% to -$61.0 million in 2023, then increased by 22.26% to -$47.4 million in 2024, then skyrocketed by 43.74% to -$26.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$26.7 million in Q3 2025, -$26.9 million in Q2 2025, and -$48.3 million in Q1 2025.